dr reddy

Nifty 50 top losers today, July 31: Adani Enterprises, Tata Steel, Sun Pharmaceutical, Dr. Reddy and more

Dr Reddy’s Laboratories Q1 Results: Revenue jumps 11.4% YoY to Rs 8,545 crore, net profit marginally up

Dr Reddy’s shares surge 5% as Trump exempts pharma exports from reciprocal tariff

Dr. Reddy’s receives USFDA EIR for Hyderabad API facility, inspection classified as ‘VAI’

Dr. Reddy’s surges 2.5% as Nomura upgrades to ‘Buy’ with ₹1,500 target

Dr Reddy’s launches immunity-boosting gummies for children

Dr Reddy’s Laboratories on announced the launch of CeleHealth Kidz Immuno Plus Gummies in India.

Dr. Reddy’s subsidiary Aurigene Oncology has halted a psoriasis medication clinical trial in the US

Following phase 2 results, the company's CEO stated that the treatment would not provide a desirable benefit to patients with moderate to severe psoriasis, hence the company chose to discontinue clinical research of AUR101 as an oral therapy in psoriasis.

Dr. Reddy’s Q4 consolidated net profit drops by 76%, despite 15% increase in revenue

On May 19, Dr Reddy's Laboratories announced a 76 percent drop in its consolidated net profit to Rs 88 crore, well below analysts' projections of Rs 677 crore.

Delay in commercial launch of Sputnik V, says Dr Reddy

Russia would import the first 50 million jabs ensuring a speedier rollout before the Indian pharmaceuticals company’s start producing the Sputnik V vaccines.